This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulv
- Study number:
- NCT05646862
- Cohorts:
- 1
- Study phase:
- 3
- Overall status:
- Not yet recruiting
- Study type:
- Targeted therapy, Hormonal therapy